BioStock: Tumorad clinical start around the corner for Spago Nanomedical

Encouraged by positive preclinical data with Tumorad, Spago Nanomedical has intensified preparations for the upcoming phase I/IIa study in cancer patients. The company also reported advancements with the contrast agent SpagoPix. BioStock reached out to CEO Mats Hansen for a comment on the Q1 report.

Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2023/05/tumorad-clinical-start-around-the-corner-for-spago-nanomedical/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/